| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 2.76 | -0.02 (-0.72%) | 1.84 - 18.90 | 278.3 thousand (Below Avg) |
Market data as of 4:00PM 06/17/13. Quotes are delayed by at least 15 min.
| Open | 2.80 |
|---|---|
| Previous Close | 2.78 |
| Day's Range | 2.75 - 2.82 |
| Market Cap | 16.7M |
| Avg Volume (10 Day) | 414.6K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -3.6 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Pass |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Echo Therapeutics Announces Pricing of Public Offering of Common Stock
PR Newswire - Thursday 06/13/2013 7:30 PM ET
Echo Therapeutics Submits Pre-Submission Package to FDA for Symphony® CGM System
PR Newswire - Monday 06/10/2013 7:50 AM ET
Echo Therapeutics Announces Reverse Split of Common Stock
PR Newswire - Thursday 06/06/2013 4:30 PM ET
Echo Therapeutics Initiates CE Mark Clinical Trial of its Symphony® CGM System
PR Newswire - Wednesday 06/05/2013 7:50 AM ET
Echo Therapeutics to Present at the Jefferies Global Healthcare Conference
PR Newswire - Thursday 05/30/2013 7:50 AM ET
Notified Body Accepts Echo Therapeutics' Clinical Trial Plan for Symphony® CGM System
PR Newswire - Wednesday 05/29/2013 7:50 AM ET
Echo Therapeutics Announces Successful Unveiling of Symphony® CGM System
PR Newswire - Thursday 05/23/2013 2:28 PM ET
Echo Therapeutics Announces Institutional Review Board (IRB) Approval for Its Clinical Trial of the Symphony® CGM System
PR Newswire - Tuesday 05/21/2013 7:50 AM ET
| ECTE | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -101.31% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | -5174.35 |
| Company | Last | Change |
|---|---|---|
| Novogen Ltd | 4.20 | -2.33% |
| Tranzyme Inc | 0.54 | -1.80% |
| Aoxing Pharmaceutical Company Inc | 0.25 | +6.38% |
| China Pharma Holdings Inc | 0.24 | +3.07% |
| Skystar Bio-Pharmaceutical Co | 1.38 | +10.40% |
Data is delayed by at least 15 min.